Amylyx Pharmaceuticals, Inc. (AMLX) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $226.65M | +192.9% |
| 2024 | $77.39M | -54.5% |
| 2023 | $170.20M | +172.2% |
| 2022 | $62.53M | +24.6% |
| 2021 | $50.19M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $226.65M | +192.9% |
| 2024 | $77.39M | -54.5% |
| 2023 | $170.20M | +172.2% |
| 2022 | $62.53M | +24.6% |
| 2021 | $50.19M | — |